Braveheart Bio, Inc.
For the period ended Jun 30, 2026. Filed Sep 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Sep 8, 2026
BRVE$19.62+0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
Condensed Statement of Cash Flows (unaudited)
(in thousands)
| Six Months EndedJune 30, 2026 | Six Months EndedJune 30, 2025 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(29,268) | $(480) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Acquired in-process research and development | — | 448 |
| Depreciation and amortization | 5 | — |
| Stock-based compensation | 2,846 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (462) | (8) |
| Accounts payable | 936 | — |
| Accrued expenses and other current liabilities (includes related party amounts of $389 and $0, respectively) | 3,912 | 40 |
| Operating lease right-of-use asset and lease liabilities | (105) | — |
| Net cash used in operating activities | (22,136) | — |
| Cash flows from investing activities: | ||
| Cash paid for purchased in-process research and development (includes related party amounts of $3,000 and $0, respectively) | (3,000) | — |
| Purchase of property and equipment | (28) | — |
| Net cash used in investing activities | (3,028) | — |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock | — | 2 |
| Proceeds from issuance of Series A redeemable convertible preferred stock, net of issuance costs | 59,596 | — |
| Payments for deferred offering costs | (762) | — |
| Net cash provided by financing activities | 58,834 | 2 |
| Net increase in cash and cash equivalents for the period | 33,670 | 2 |
| Cash and cash equivalents at beginning of the period | 89,161 | — |
| Cash and cash equivalents at end of the period | $122,831 | $2 |
| Supplemental disclosure of cash flow information: | ||
| Non-cash investing and financing activities: | ||
| Right-of-use assets obtained in connection with operating lease obligations | $795 | $— |
| Deferred offering costs in accounts payable and accrued liabilities | $2,050 | $— |
| Non-cash deemed dividends on Series A redeemable convertible preferred stock | $3,615 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.